On May 17, 2023, NHS England issued an updated version of the National Genomic Test Directory for cancer (version 7), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs.
Two new codes (test-indication combinations) were introduced in the Test Directory for cancer for multi-target NGS panel-small variant (BRCA1, BRCA2) germline testing in breast and prostate cancer.
The document specifying eligibility criteria for rare and inherited diseases Directory was also updated (version 5.1); however, no new codes were added, and only minor amendments were made.
See the full details here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).